血清生物标志物在创伤性颅脑损伤中的临床应用:按损伤严重程度分层的系统综述
该系统综述检索PubMed/Medline并遵循PRISMA,纳入115篇全文文献、报告94种生物标志物,按GCS、影像异常及损伤严重度评分分层,总结其诊断与预后价值。多种标志物与诊断和预后变量显著相关,且在轻、中、重度TBI及脑震荡中水平差异显著。
要点
- 多种血清标志物在TBI诊断与预后评估中具有显著相关性。
- 标志物水平在轻、中、重度TBI及脑震荡间存在显著差异。
- 证据支持按损伤严重程度选用相应生物标志物。
核心结论
- 现有高质量证据支持在TBI诊断与预后评估中使用按严重程度分层的生物标志物。
研究设计与样本
- 系统综述,检索PubMed/Medline并按PRISMA执行,排除未提供新数据的系统综述与meta分析。
- 初筛1463项研究,最终纳入115篇全文文献,报告94种不同生物标志物。
- 采用美国心脏病学会/美国心脏协会标准评估证据水平。
主要发现
- 最常用的临床诊断变量为GCS评分、CT/MRI异常及损伤严重度评分。
- 最常用的临床预后变量为GOS及1、3、6个月死亡率。
- 多种标志物与上述变量显著相关,且与健康、骨科及多发伤对照相比水平有统计学显著差异。
- 标志物在轻度、中度、重度TBI及脑震荡病例中显示显著变异。
临床怎么用
- 可依据TBI严重程度选择相应血清标志物辅助诊断与预后评估。
- 现有数据可作为后续临床验证研究的启动平台。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Serum biomarkers have gained significant popularity as an adjunctive measure in the evaluation and prognostication of traumatic brain injury (TBI). However, a concise and clinically oriented report of the major markers in function of TBI severity is lacking. This systematic review aims to report current data on the diagnostic and prognostic utility of blood-based biomarkers across the spectrum of TBI. METHODS: A literature search of the PubMed/Medline electronic database was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We excluded systematic reviews and meta-analyses that did not provide novel data. The American College of Cardiology/American Heart Association criteria were used to assess levels of evidence. RESULTS: An initial 1463 studies were identified. In total, 115 full-text articles reporting on 94 distinct biomarkers met the inclusion criteria. Glasgow Coma Scale scores, computed tomography/magnetic resonance imaging abnormalities, and injury severity scores were the most used clinical diagnostic variables. Glasgow Outcome Scores and 1-, 3-, and 6-month mortality were the most used clinical prognostic variables. Several biomarkers significantly correlated with these variables and had statistically significant different levels in TBI subjects when compared with healthy, orthopedic, and polytrauma controls. The biomarkers also displayed significant variability across mild, moderate, and severe TBI categories, as well as in concussion cases. CONCLUSIONS: This review summarizes existing high-quality evidence that supports the use of severity-specific biomarkers in the diagnostic and prognostic evaluation of TBI. These data can be used as a launching platform for the validation of upcoming clinical studies.
引用
- Al-Adli N, Akbik OS, Rail B, et al. The Clinical Use of Serum Biomarkers in Traumatic Brain Injury: A Systematic Review Stratified by Injury Severity. World Neurosurg. 2021. PMID: 34438102. doi:10.1016/j.wneu.2021.08.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。